CSL Limited

Money Moves

Co-developer and commercial partner for lixudebart

CSL will pay Alentis Therapeutics $355 million upfront to co-develop lixudebart, an antibody for rare kidney and liver diseases. Milestones could add $1.2 billion, with profits split 55% to CSL and 45% to Alentis, and CSL is funding every trial, which the Australian Financial Review puts at up to $2.2 billion in total.

Updated Oct 24

Money Moves

Acquirer; adds North American operations

London-based CSL Group, a provider of connectivity for industrial IoT devices, bought US eSIM company SIMPL Wireless on October 16. The deal gives CSL its first North American base and adds a platform that manages SIMs across up to 100 mobile carriers from a single dashboard.

Updated Oct 21